110 related articles for article (PubMed ID: 23469798)
1. [Metabolic complications and quality of life in prostate cancer patients after receiving endocrine treatment].
Yuan JQ; Xu T; Zhang XW; Wang XF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Feb; 35(1):88-94. PubMed ID: 23469798
[TBL] [Abstract][Full Text] [Related]
2. [Maximal androgen blockade little influences bone mineral density in prostate cancer patients].
Sun GF; Yang B; Zhu H; Li NC; Na YQ
Zhonghua Nan Ke Xue; 2012 Nov; 18(11):978-81. PubMed ID: 23214245
[TBL] [Abstract][Full Text] [Related]
3. Metabolic syndrome and androgen deprivation therapy in metabolic complications of prostate cancer patients.
Yuan JQ; Xu T; Zhang XW; Yu LP; Li Q; Liu SJ; Huang XB; Wang XF
Chin Med J (Engl); 2012 Oct; 125(20):3725-9. PubMed ID: 23075732
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
[TBL] [Abstract][Full Text] [Related]
5. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
[TBL] [Abstract][Full Text] [Related]
6. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
7. Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients.
Deng JH; Yang LP; Wang LS; Zhou DF
Asian J Androl; 2004 Mar; 6(1):75-7. PubMed ID: 15064839
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
9. [Influence of androgen deprivation therapy on bone mineral density in men with prostate cancer].
Deng J; Li W; Yang L; Wang L; Zou D
Zhonghua Nan Ke Xue; 2004 Oct; 10(10):761-3. PubMed ID: 15562791
[TBL] [Abstract][Full Text] [Related]
10. Investigative clinical study on prostate cancer part IV: exploring functional relationships of total testosterone predicting free testosterone and total prostate-specific antigen in operated prostate cancer patients.
Porcaro AB; Petrozziello A; Migliorini F; Lacola V; Romano M; Sava T; Ghimenton C; Caruso B; Zecchini Antoniolli S; Rubilotta E; Monaco C; Comunale L
Urol Int; 2011; 86(4):399-406. PubMed ID: 21508618
[TBL] [Abstract][Full Text] [Related]
11. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
12. Testosterone recovery and changes in bone mineral density after stopping long-term luteinizing hormone-releasing hormone analogue therapy in osteoporotic patients with prostate cancer.
Weston R; Hussain A; George E; Parr NJ
BJU Int; 2005 Apr; 95(6):776-9. PubMed ID: 15794781
[TBL] [Abstract][Full Text] [Related]
13. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?
Perachino M; Cavalli V; Bravi F
BJU Int; 2010 Mar; 105(5):648-51. PubMed ID: 19747358
[TBL] [Abstract][Full Text] [Related]
14. Investigative clinical study on prostate cancer part IX and X: estradiol and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy.
Porcaro AB; Ghimenton C; Petrozziello A; Sava T; Migliorini F; Romano M; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C
Anticancer Res; 2012 Oct; 32(10):4523-32. PubMed ID: 23060581
[TBL] [Abstract][Full Text] [Related]
15. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Appu S; Lawrentschuk N; Grills RJ; Neerhut G
J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.
Spry NA; Galvão DA; Davies R; La Bianca S; Joseph D; Davidson A; Prince R
BJU Int; 2009 Sep; 104(6):806-12. PubMed ID: 19281463
[TBL] [Abstract][Full Text] [Related]
18. Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients.
Yuasa T; Maita S; Tsuchiya N; Ma Z; Narita S; Horikawa Y; Yamamoto S; Yonese J; Fukui I; Takahashi S; Hatake K; Habuchi T
Urology; 2010 May; 75(5):1131-7. PubMed ID: 20163839
[TBL] [Abstract][Full Text] [Related]
19. Effect of androgen suppression on bone mineral density in patients with prostate cancer.
Chernichenko OA; Sakalo VS; Yakovlev PG; Sakalo AV; Zhylchuk YV; Zsolt A
Exp Oncol; 2014 Dec; 36(4):276-8. PubMed ID: 25537224
[TBL] [Abstract][Full Text] [Related]
20. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
